Moleculin Biotech begins dosing in Phase 1a clinical trial of COVID-19 candidate » 08:3905/2605/26/22
Moleculin Biotech commenced dosing in its first-in-human Phase 1a study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19. The Phase 1a, first-in-human, overlapping Single and Multiple ascending dose will investigate the effects of WP1122 administered as an oral solution in healthy human volunteers in the U.K. This study in healthy volunteers will explore safety and PK, and subsequent antiviral clinical development will be in patients infected with SARS-CoV-2 to further evaluate safety and establish a favorable risk/benefit profile. Moleculin is also in the process of identifying additional countries where potential future Phase 2 COVID-19 clinical studies could occur.
Aeterna Zentaris partner Consilient announces European launch of Ghryvelin » 08:1305/2505/25/22
Aeterna Zentaris announced that Ghryvelin, the first oral test approved for diagnosing Growth Hormone Deficiency in adults, is now available to healthcare professionals across Europe. This availability is possible thanks to Aeterna's licensing partner, Consilient Health, a privately owned pharmaceutical company focused on commercializing medicines in Europe and Middle East. European approval of Ghryvelin was granted in 2019, based on Phase 3 data showing that oral macimorelin provides accuracy comparable to that of standard insulin tolerance testing, but has a considerably more favorable safety profile compared to ITT. Oral Ghryvelin also reduces false positive test results, helping to avoid unnecessary treatment of patients. Aeterna's licensing partner, Novo Nordisk is currently marketing macimorelin in the United States under the tradename Macrilen.
|Over a week ago|
SinglePoint's BOX Pure Air assisting schools in areas with wildfire smoke » 08:3905/1905/19/22
SinglePoint subsidiary BOX Pure Air is actively assisting schools looking for immediate solutions to continue safely operating by addressing indoor air quality, IAQ, for students, teachers and staff in areas affected by wildfire smoke in an attempt to prevent unplanned school closures. Wil Ralston, CEO of SinglePoint commented, "For too long we have ignored the poor health conditions and the catastrophic effects of poor indoor air quality. Clean air is an essential right and we have a solution that can immediately improve indoor air quality in the places we gather, whether that be at home, at work, or at school. The particle size associated with wildfire pollution can quickly and dramatically harm anyone who breathes it in, but the portable HEPA air filtration system we offer cleanses the air of these pollutants, reducing the risk. Schools and students cannot afford to miss additional days due to dangers of the air they breathe indoors, especially when there is a simple, portable and effective solution."
American Resources signs offtake, financial partnership with Integrity Coal » 08:3105/1805/18/22
American Resources announced that it has signed a carbon offtake agreement along with a non-dilutive financial commitment of $2.5 million with a long-standing customer and premier supplier of metallurgical carbon to the global steel and alloy metal marketplace, Integrity Coal Sales, to start its Carnegie 2 mine. This incremental production will enable the Company to benefit from the current strength in the high vol met carbon market, aligning the risk and return for both Integrity and American Resources. High Vol metallurgical carbon is not burned for energy use. Instead, specific characteristics allow it to be blended with iron to make new steel. This quality of product is in high demand in the current market environment given many of the producers in the U.S. are producing from old mines that are expensive to operate and coming to end-of-life. American Resources is focused on mine plans and operations that are built to be low cost once ramped ranging from 20 to 40+ years while also making them safer and more productive operations. Post initial production ramp Carnegie 2 is anticipating adding $25 to $35 million in additional yearly revenue to the company's top line with attractive margins.
AIM ImmunoTech provides update on Ampligen long-COVID program » 08:1105/1805/18/22
AIM ImmunoTech provided…
AIM ImmunoTech provided an update on its ongoing efforts to develop an effective therapeutic for "Long COVID" with its investigational drug, Ampligen. A Phase 3 prospective, double-blind, randomized, placebo-controlled trial of rintatolimod in ME/CFS produced objective improvement in exercise tolerance. An analysis of a subset of patients in that trial with early onset of symptoms showed a statistically significant 51.2% positive response. In an amendment to its ongoing, FDA-authorized AMP-511, AIM enrolled four post-COVID patients with new onset ME/CFS following acute COVID-19. Following at least 12 weeks of Ampligen treatment, each of these four patients indicated they had experienced a reduction in fatigue, as measured via Patient-Reported Outcomes questionnaires. A statistical analysis of these data indicated that the decrease in fatigue compared to baseline was statistically significant, despite the small number of patients. Based in part on these early positive data, AIM is working toward filing an Investigational New Drug application with the U.S. Food and Drug Administration for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions. The newly planned IND is for 12 weeks of therapy. AIM CEO Thomas Equels stated: "While the recently published positive data in pancreatic cancer, advanced recurrent ovarian cancer and triple-negative breast cancer make Ampligen in oncology a top priority, we remain dedicated in our efforts to develop an effective therapy for ME/CFS and Long COVID. Millions of people have suffered too long from these debilitating conditions, and we are steadfast in our mission to help alleviate their suffering."
Cyclo Therapeutics to host virtual investor event » 13:4505/1605/16/22
Virtual Investor Niemann-Pick Disease Type C Spotlight Event to be held on May 16 at 2 pm. Webcast Link
Cyclo Therapeutics to host virtual investor event » 09:4605/1605/16/22
Virtual Investor Niemann-Pick Disease Type C Spotlight Event to be held on May 16 at 2 pm. Webcast Link
American Resources, Novusterra enter partnership with Kenai Defense » 09:3305/1605/16/22
American Resources Corporation alongside its affiliate, Novusterra, has entered into an exclusive license arrangement with Kenai Defense Company to further develop and commercialize carbon nanostructure and graphene technologies in partnership with its defense and space industry relationships. Additionally, Kanai has agreed to hit certain milestones, funding commitments for the technology and commercialization dates of which it will pay a split of cashflow generated to American Rare Earth and Novusterra. For federal fiscal year 2022, Kenai anticipates Air Force contracts exceeding $1.5 million to develop advanced applications using carbon nanostructure and graphene for concrete additive. For fiscal year 2023, Kenia anticipates an additional $10 million of development funding in partnership with the United States Department of Defense. These partnerships are focused on using carbon nanostructures and graphene to increase the strength, reduce cure time and provide a more sustainable and durable concrete product for defense infrastructure. American Resources Corporation and Novusterra will equally share in the 20% cash flow stream received from Kenai.
Aeterna Zentaris urges shareholders to vote for proposed share consolidation » 08:2805/1605/16/22
Aeterna Zentaris announced that its Virtual Annual General and Special Meeting of shareholders will be held on June 21, 2022, at 10:00 a.m. Management and the board of directors urge the Company's shareholders of record to vote "FOR" the resolution authorizing the Board to approve a share consolidation of the Company's issued and outstanding common shares. The platform for the virtual AGM will provide shareholders the ability to listen to the AGM live, submit questions and submit their vote during the AGM. Online check-in will begin 15 minutes prior to the start of the AGM, at 9:45 a.m. The AGM will begin promptly at 10:00 a.m. on June 21, 2022. A management information circular describing the proposed share consolidation and other items of business to be considered at the AGM will be mailed to shareholders in the coming days. Remaining on the Nasdaq Capital Market is a critical piece of the Company's performance, corporate visibility and overall awareness of Aeterna Zentaris to the investor base. If the Company fails to meet a minimum bid price for its common shares above US$1.00, for a minimum of at least 10 consecutive days before July 26, 2022, the Company could be delisted from The Nasdaq Stock Market, which could have serious consequences for the Company. Accordingly, the Company expects to file a management information circular in the coming days which will include a resolution for shareholders to provide the Board with the authority to consolidate the common shares at a ratio within the range of between five and 25 pre-consolidation common shares for every one post-consolidation common share. The Company expects that the Share Consolidation will allow for the common shares to continue to be listed on the Nasdaq, and ensure compliance with the Nasdaq's continued listing standard that common shares maintain a minimum bid price of US$1.00 per share. As previously announced, on July 28, 2021, the Company received a letter from the Listing Qualifications Department of the Nasdaq, indicating that, based upon a closing bid price of less than $1.00 per share for the Company's common shares for the prior 30 consecutive business day period, the Company no longer satisfied Nasdaq Listing Rule 5550(a)(2). In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), the Company was granted a grace period of 180 calendar days, through January 24, 2022. On January 26, 2022, the Company announced that the Nasdaq granted the Company an additional 180 calendar day period, through July 26, 2022, to comply with the Standard. In advance of the Deadline, the Board believes it is in the best interests of the Company to obtain shareholder approval at the Meeting to implement the Share Consolidation.
AIM ImmunoTech expects cash to fund operations through 2023 » 07:2105/1605/16/22
As of March 31, 2022, AIM…
As of March 31, 2022, AIM reported cash and cash equivalents of $44.5 million. Based on management's current expectation, the Company's cash runway is expected to fund operations through 2023.